INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $746 | -16.9% | 14,327 | +1.1% | 0.01% | -14.3% |
| Q2 2023 | $898 | +27.7% | 14,175 | +9.1% | 0.01% | +16.7% |
| Q1 2023 | $703 | -11.7% | 12,988 | -13.6% | 0.01% | -14.3% |
| Q4 2022 | $796 | -99.9% | 15,036 | +1.4% | 0.01% | 0.0% |
| Q3 2022 | $690,000 | -17.6% | 14,823 | +1.1% | 0.01% | -12.5% |
| Q2 2022 | $837,000 | +3.8% | 14,662 | +11.3% | 0.01% | +33.3% |
| Q1 2022 | $806,000 | -38.1% | 13,172 | -47.0% | 0.01% | +20.0% |
| Q4 2021 | $1,302,000 | +177.6% | 24,876 | +97.9% | 0.01% | +25.0% |
| Q3 2021 | $469,000 | -13.9% | 12,573 | -5.8% | 0.00% | 0.0% |
| Q2 2021 | $545,000 | +132.9% | 13,346 | +93.3% | 0.00% | -55.6% |
| Q1 2021 | $234,000 | -1.7% | 6,905 | -7.9% | 0.01% | 0.0% |
| Q4 2020 | $238,000 | -13.5% | 7,496 | -6.4% | 0.01% | +80.0% |
| Q4 2019 | $275,000 | – | 8,009 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |